
MaxCyte, Inc. (MXCT) Market Cap
MaxCyte, Inc. has a market capitalization of $91.8M.
Financials based on reported quarter end 2025-12-31
Price: $0.86
βΌ -0.03 (-3.53%)
Market Cap: 91.77M
NASDAQ Β· time unavailable
CEO: Maher Masoud
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2021-07-30
Website: https://maxcyte.com
MaxCyte, Inc. (MXCT) - Company Information
Market Cap: 91.77M Β· Sector: Healthcare
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Analyst Sentiment
Based on 6 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 2 sources)
Consensus Price Target
Low
$6
Median
$6
High
$6
Average
$6
Potential Upside: 598.6%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
π AI Financial Analysis
Powered by StockMarketInfo"MXCT reported revenue of $7.3M with a net loss of $9.6M and an EPS of -$0.1. The company is experiencing significant challenges, evidenced by a 1-year price decline of 76.51% and negative operating cash flow of $2.7M. While the total assets stand at $202.5M, the liabilities amount to $31.0M, leading to a positive net debt of $2.1M. The overall financial health reflects substantial losses and cash outflows, indicating potential sustainability concerns. Notably, the company has not distributed dividends and faces pressure regarding market performance. Analysts currently set a median price target of $6, which is significantly higher than the current price of $0.74, suggesting potential upside if the company addresses its operational issues and stabilizes its performance."
Revenue Growth
Minimal revenue growth; substantial losses reported.
Profitability
Negative net income and EPS indicate poor profitability.
Cash Flow Quality
Operating cash flow is negative, indicating cash burn.
Leverage & Balance Sheet
Strong equity position relative to liabilities.
Shareholder Returns
No dividends and poor stock price performance.
Analyst Sentiment & Valuation
Analysts see potential upside, but current market performance is weak.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Managementβs tone is upbeat on fundamentals and longer-term platform differentiation (ExPERT DTX traction, CASGEVY ramp, SecurDx growth). However, the Q&A pressure reveals why core revenue declines are expected to deepen in 2026: management attributes it largely to a discrete ~$4M core revenue headwind embedded in guidanceβsplit roughly half leases lost from SPL customers that exited/terminated and half processing assemblies tied to the largest customerβs supply-chain and inventory drawdown, plus a midyear lease reduction from manufacturing footprint reoptimization. Analysts challenged whether share is being lost; management explicitly denies deterioration of fundamentals and frames upside as industry demand improving, but the company is already baking in customer-specific contraction and timing effects. The clearest operational hurdle is customer inventory/lease normalization rather than a market collapse, while milestone/royalty assumptions (haircut/timing) and SPL sign cadence (expect at least three; first potentially early/mid second half) remain key swing factors for the revenue recovery narrative.
Growth Catalysts
- Launch of ExPERT DTX (modular 96-well electroporation) designed to remove transfection as an experimental variable; enables workflow continuity from discovery through cGMP platforms without reoptimization
- CASGEVY ramp (commercial royalty/usage ramp expected throughout 2026)
- SecurDx expected year-over-year growth in 2026 as integration matures and regulatory environment favors off-target risk assessment
Business Development
- SPL portfolio scale: 31 SPL agreements total; four new SPLs signed in 2025
- New and later-stage clinical pipeline includes named programs expected to enter pivotal studies within 18 months: zuma-cell (CRISPR Therapeutics), Wu-CAR-T-007 (WuXi-GENE), Asia-cell (Imugene), and two undisclosed SPL partners
- Commercial therapy supported: CASGEVY (Vertex/CRISPR ecosystem mentioned; Vertex reiterated multibillion-dollar potential)
Financial Highlights
- Full-year revenue: $33.0M (down from $38.6M in 2024; -15%)
- Full-year core revenue: $29.6M (down from $32.5M; -9%)
- Full-year SPL program-related revenue: $3.4M (down from $6.1M; -~45%)
- Q4 2025 revenue: $7.3M (down from $8.7M; -16%)
- Q4 core revenue: $6.8M (down from $8.6M; -22%)
- Q4 gross margin: 78% vs 74% in Q4 2024; excluding inventory provisions and SPL program-related revenue, non-GAAP adjusted gross margin 78% vs 84%
- Operating expenses Q4 2025: $9.0M vs $19.3M in Q4 2024; impacted by non-cash goodwill impairment of $3.6M in Q4
- No debt; cash, cash equivalents, and investments: $155.6M at end of 2025
- 2025 mix: SPL-derived core revenue 47% vs 55% in 2024 (reflecting program exits and reduced purchasing from largest commercial-stage partner)
- 2026 guidance: total revenue $30M-$32M; core $25M-$27M; SPL program-related $5M
- 2026 guidance headwinds baked in: approx. $4M core revenue headwind vs 2025 (about half Processing Assemblies, half leases)
- 2026 guidance for SPL program-related revenue includes: ~$2M expected commercial royalty revenue and remainder milestones; mentions a seven-figure milestone received in Q1 2026
Capital Funding
- No debt as of year-end 2025
- Cash runway: company anticipates at least $136M in cash/cash equivalents/investments at end of 2026
- Reduced annual cash burn by over $16M in 2025 via restructuring/cost-efficiency actions
Strategy & Ops
- Restructured to right-size spending; company states it does not expect meaningful operating expense growth from current levels
- Integration of acquired SecurDx into MaxCyte (2025 integration continues into 2026)
- Cost structure: entered 2026 on a βdramatically different spending trajectoryβ vs prior operating model
Market Outlook
- 2026 quarterly shape: Q1 expected to be lightest quarter for core revenue; back half weighted year
- Guidance incorporates SPL customer license termination not related to platform performance (began impacting 2025; continues into 2026)
- SPL agreement cadence expectation: continue signing at least 3 in 2026; reaffirmed 3-5/year framing (though first signing visibility shifted to early/mid second half timing)
Risks & Headwinds
- Largest stated hurdle: $4M core revenue headwind in 2026 relative to 2025 due to: (i) leases lost from SPL customers/program exits (about half of $4M; especially impacts first half), and (ii) processing assemblies impact from largest customerβs inventory drawdown/reorganization plus midyear reduction in leases due to manufacturing site reorganization (second half impact)
- License termination from an SPL customer for reasons unrelated to platform performance; included in 2026 guidance
- Program rationalization: lost six SPL clinical programs during 2025; annualized revenue from discontinued programs will not recur in 2026
- Comparability headwind at largest customer: lease revenue has difficult year-over-year comparison due to midyear lease reduction following site reorganization; company expects stabilization during 2026
- Non-GAAP gross margin dilution: adjusted gross margin 78% vs 84% in Q4 2024 (excluding inventory provisions and SPL program-related revenue)
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the MXCT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.





